Doximity Inc. Class A Common Stock (DOCS)
StalwartFairStock Score: 61/100 — STEADY
Key Financials
| Current Price | $18.97 |
| Market Cap | $4.4B |
| P/E Ratio | 19.36 |
| ROE | 19.28% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $214 million in annual free cash flow (4.9% yield on market cap)
- High return on equity of 23.8% demonstrating efficient capital deployment
- Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
- Altman Z-Score of 16.0 confirms minimal bankruptcy risk and strong solvency
Concerns
- Trades significantly above Graham Number ($12) with negative 94% margin of safety—limited downside protection
AI Analysis
Doximity Inc. Class A Common Stock is a small-cap healthcare company valued at $4.4 billion. The business generates $638 million in annual revenue with a 9.7% net margin and $214 million in free cash flow. From a quality standpoint, Doximity shows Altman Z-Score of 16.0 confirms fortress-level solvency and strong 24% ROE. On valuation, the stock is reasonably priced at 19.5x earnings, with trades above its Graham Number with a negative 94% margin. Growth dynamics show revenue growing at 9.8% and profit growth of -18.1%. Our composite FairStock Score of 61/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $214 million in annual free cash flow (4.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer